Abstract:  Immune rejection after corneal penetrating keratoplasty is still one of the main reasons leading failure of the surgery, especially in high-risk cases, in whom the rejection ratio can be as high as 50%. Glucocorticoid is still the first-line drug for the prevention and treatment of corneal graft rejection, and topical application of which is the main way of administration, but long-term using of which should be paid more attention to avoiding the side effects. Cyclosporin A (CsA) eye drops in combination with glucocorticoid can be better to prevent immune rejection episodes and reduce the side effects of steroid. Topical tacrolimus application also showes a good result.

Key words: corneal transplantation, immune rejection, immunosuppressant